<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001767215</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001100682</issuerCik>
      <issuerName>Charles River Laboratories</issuerName>
      <secFileNumber>001-15943</secFileNumber>
      <issuerAddress>
        <com:street1>251 Balardvale Street</com:street1>
        <com:city>Wilmington</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>01887</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>781-222-6000</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Joseph LaPlume</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>UBS Financial Services Inc</name>
        <address>
          <com:street1>1000 Harbor Blvd</com:street1>
          <com:street2>3rd Floor</com:street2>
          <com:city>Weehawken</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07086</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>800</noOfUnitsSold>
      <aggregateMarketValue>125600</aggregateMarketValue>
      <noOfUnitsOutstanding>49120000</noOfUnitsOutstanding>
      <approxSaleDate>08/18/2025</approxSaleDate>
      <securitiesExchangeName>NYSE</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>COMMON</securitiesClassTitle>
      <acquiredDate>01/27/2023</acquiredDate>
      <natureOfAcquisitionTransaction>PERFORMANCE STOCK UNIT</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>CHARLES RIVER LABORATORIES</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>8342</amountOfSecuritiesAcquired>
      <paymentDate>08/18/2025</paymentDate>
      <natureOfPayment>CASH</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Joseph LaPlume</name>
        <address>
          <com:street1>c/o Charles River Laboratories</com:street1>
          <com:street2>251 Balardvale Street</com:street2>
          <com:city>Wilmington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01887</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <saleDate>08/07/2025</saleDate>
      <amountOfSecuritiesSold>400</amountOfSecuritiesSold>
      <grossProceeds>59991</grossProceeds>
    </securitiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>08/18/2025</noticeDate>
      <signature>/s/JOSEPH  CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Joseph LaPlume</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
